
Séverine Chaumont-Dubel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/890350/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	5â€HT ₆ receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Molecular Medicine, 2012, 4, 1043-1056.	6.9	152
2	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews, 2021, 73, 310-520.	16.0	127
3	Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. Nature Chemical Biology, 2014, 10, 590-597.	8.0	95
4	Physical interaction between neurofibromin and serotonin 5-HT ₆ receptor promotes receptor constitutive activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12310-12315.	7.1	71
5	Novel 1 <i>H</i> -Pyrrolo[3,2- <i>c</i>]quinoline Based 5-HT ₆ Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 972-983.	3.5	64
6	5-HT ₆ Receptor: A New Player Controlling the Development of Neural Circuits. ACS Chemical Neuroscience, 2015, 6, 951-960.	3.5	51
7	The serotonin 6 receptor controls neuronal migration during corticogenesis via a ligand-independent Cdk5-dependent mechanism. Development (Cambridge), 2014, 141, 3370-3377.	2.5	49
8	Novel non-sulfonamide 5-HT 6 receptor partial inverse agonist in a group of imidazo[4,5- b]pyridines with cognition enhancing properties. European Journal of Medicinal Chemistry, 2018, 144, 716-729.	5.5	37
9	The 5-HT6 receptor interactome: New insight in receptor signaling and its impact on brain physiology and pathologies. Neuropharmacology, 2020, 172, 107839.	4.1	31
10	Dual 5-HT ₆ and D ₃ Receptor Antagonists in a Group of 1 <i>H</i> -Pyrrolo[3,2- <i>c</i>]quinolines with Neuroprotective and Procognitive Activity. ACS Chemical Neuroscience, 2019, 10, 3183-3196.	3.5	24
11	The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication. Nature Communications, 2020, 11, 4855.	12.8	21
12	mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. Progress in Neurobiology, 2020, 193, 101846.	5.7	20
13	Early 5― <scp>HT</scp> ₆ receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Molecular Medicine, 2020, 12, e10605.	6.9	18
14	Dynamic interactions of the 5-HT ₆ receptor with protein partners control dendritic tree morphogenesis. Science Signaling, 2020, 13, .	3.6	16
15	A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties. European Journal of Medicinal Chemistry, 2020, 208, 112765.	5.5	15
16	Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor. Progress in Neurobiology, 2021, 197, 101900.	5.7	15
17	Imidazopyridine-Based 5-HT ₆ Receptor Neutral Antagonists: Impact of <i>N</i> ¹ -Benzyl and <i>N</i> ¹ -Phenylsulfonyl Fragments on Different Receptor Conformational States. Journal of Medicinal Chemistry, 2021, 64, 1180-1196.	6.4	14
18	Novel and atypical pathways for serotonin signaling. Faculty Reviews, 2021, 10, 52.	3.9	14

#	Article	IF	CITATIONS
19	Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT ₃ and 5-HT ₆ Receptor Antagonist with Antipsychotic and Procognitive Properties. Journal of Medicinal Chemistry, 2021, 64, 13279-13298.	6.4	14
20	2-Phenyl-1 <i>H</i> -pyrrole-3-carboxamide as a New Scaffold for Developing 5-HT ₆ Receptor Inverse Agonists with Cognition-Enhancing Activity. ACS Chemical Neuroscience, 2021, 12, 1228-1240.	3.5	9
21	Neuropathic pain-alleviating activity of novel 5-HT6 receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide. Bioorganic Chemistry, 2021, 115, 105218.	4.1	4